The UK and US have forged a important bilateral deal that will maintain zero duties on British drug products going into the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has agreed to boost expenditure on pharmaceuticals through the NHS. This move guarantees that tariffs on these vital products will be held at nothing for a duration of 36 months.
This development is in response to recent warnings to significantly raise import taxes on branded drug imports, with increases discussed reaching 100%.
"This deal between the Britain strengthens the worldwide climate for innovative medicines and introduces much-needed equity to U.S.–U.K. medicine commerce," a release said.
Trade Impact
Drugs constitute one of the UK's largest goods shipped to the US, which is clearly the primary destination for major companies like GSK and AstraZeneca.
Trade data reveal that in the year to the end of the third quarter, the UK sold medicines valued at over eleven billion pounds to the US. This value made up a significant portion of British export trade in that period.
"This agreement secures jobs, boosts capital expenditure and paves the way for the UK to emerge as a global hub for biotech and pharma," the Business and Trade Secretary commented.
Key NHS Changes
The deal entails several notable commitments from the UK:
- Price Threshold Increase: The UK will increase the price threshold at which it deems new treatments to be prohibitively costly by 25%.
- Higher Drug Budget: There is a target to increase total NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount drug companies must refund to the NHS to stay within budget will be restricted at 15%. Previously, repayments exceeded 20%.
Industry Background
This agreement comes amid a long-running tension between the drug companies and the UK government over drug pricing and regulatory access.
The disagreement were heightened by arguments that American customers were charged several times more for the identical medicines than consumers in the other developed nations.
Recently, several large drug company projects in the UK have been halted or abandoned, while substantial expansions have been announced toward US facilities.
The Science Minister stated that the NHS had to increase expenditure on medicines, noting that its spending on drugs had shrunk as a share of its resources over the last ten years.
